Plus Therapeutics Valuation
| PSTV Stock | USD 1.26 0.02 1.56% |
Today, the company appears to be undervalued. Plus Therapeutics holds a recent Real Value of $5.3 per share. The prevailing price of the company is $1.26. Our model determines the value of Plus Therapeutics from analyzing the company fundamentals such as Operating Margin of (2.89) %, shares outstanding of 5.9 M, and Return On Equity of -5.22 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Plus Therapeutics' valuation include:
Price Book 3.7603 | Enterprise Value 6 M | Enterprise Value Ebitda (0.30) | Price Sales 1.3486 | Enterprise Value Revenue 18.192 |
Undervalued
Today
Please note that Plus Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of Plus Therapeutics is based on 3 months time horizon. Increasing Plus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Plus stock is determined by what a typical buyer is willing to pay for full or partial control of Plus Therapeutics. Since Plus Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Plus Stock. However, Plus Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.26 | Real 5.3 | Target 17.5 | Hype 1.26 |
The intrinsic value of Plus Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Plus Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Plus Therapeutics helps investors to forecast how Plus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Plus Therapeutics more accurately as focusing exclusively on Plus Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Plus Therapeutics' intrinsic value based on its ongoing forecasts of Plus Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Plus Therapeutics' closest peers.
Plus Therapeutics Cash |
|
Plus Valuation Trend
Analysing the historical paterns of Plus Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Plus Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Plus Therapeutics Total Value Analysis
Plus Therapeutics is at this time anticipated to have valuation of 6.04 M with market capitalization of 7.43 M, debt of 4.18 M, and cash on hands of 20.27 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Plus Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.04 M | 7.43 M | 4.18 M | 20.27 M |
Plus Therapeutics Investor Information
The company recorded a loss per share of 2.33. Plus Therapeutics last dividend was issued on the 6th of August 2019. The entity had 1:15 split on the 1st of May 2023. Based on the key indicators related to Plus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Plus Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Plus Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Plus Therapeutics has an asset utilization ratio of 43.14 percent. This indicates that the Company is making $0.43 for each dollar of assets. An increasing asset utilization means that Plus Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Plus Therapeutics Ownership Allocation
Roughly 86.36 pct. of Plus Therapeutics outstanding shares are held by general public with 2.34 % owned by insiders and only 11.3 (%) by third-party entities.Plus Therapeutics Profitability Analysis
The company reported the previous year's revenue of 4.91 M. Net Loss for the year was (13.32 M) with loss before overhead, payroll, taxes, and interest of (9.47 M).About Plus Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Plus Therapeutics. We calculate exposure to Plus Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Plus Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -4.8 M | -4.5 M | |
| Pretax Profit Margin | (2.71) | (2.85) | |
| Operating Profit Margin | (3.12) | (3.27) | |
| Net Loss | (2.71) | (2.85) | |
| Gross Profit Margin | (0.97) | (0.92) |
Plus Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Plus Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 3.1 M |
Plus Therapeutics Current Valuation Indicators
Plus Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Plus Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Plus Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Plus Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Plus Therapeutics' worth.Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.